Early Phase 2 data from Processa Pharmaceuticals (Nasdaq: PCSA) reveal that NGC-Cap — a combo of PCS6422 and capecitabine — significantly boosts cancer-killing metabolite exposure without increasing toxicity compared to standard therapy. With the formal interim analysis slated for early 2026, the findings support NGC-Cap’s potential to deliver greater efficacy and better tolerability in a multi-billion-dollar breast cancer treatment market.

Greenwich LifeSciences (Nasdaq: GLSI) announced a striking ~80% reduction in recurrence rates in the open label, non-HLA-A*02 arm of its Phase III FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy targeting HER2-positive breast cancer. The data, consistent with earlier Phase IIb results, suggest GLSI-100 could set a new benchmark in recurrence prevention, outperforming current therapies like TDM1 and reinforcing its potential in a multi-billion-dollar adjuvant breast cancer market.

ASP Isotopes (Nasdaq: ASPI) has received all regulatory approvals for its acquisition of Renergen Limited, positioning the combined entity as a global leader in helium, LNG, and enriched isotopes. The strategic merger unlocks vertical integration across critical supply chains, with expected synergies beginning in 2026 and a production update from Renergen’s Virginia Gas Project anticipated in January.

Trinity Biotech (Nasdaq: TRIB) has secured multi-country regulatory clearances to roll out its next-gen high-capacity HbA1c column system for the Premier Hb9210 analyzer, now available in over 10 countries including the U.S. The system boosts testing throughput up to 4x, enhances lab efficiency, and expands recurring revenue potential as the company accelerates penetration into the fast-growing $2B+ global HbA1c market projected to surpass $3.5B by 2030.